33 results about "Roseburia" patented technology

The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced.

The present invention relates to a biomarker for risk prediction or diagnosis of metabolic and inflammatory diseases, and use thereof. The biomarker is formulated to detect a group of microorganisms consisting of Akkermansia muciniphila, Bacteroides spp., Eubacterium spp., Roseburia spp., Methanobrevibacter smithii, Methanosphaera stadtmanae, Ruminococcus obeum, and Phascolarctobacterium.

The invention relates to the fields of genetic engineering and biomedicine, and more specifically relates to a biomarker of schizophrenia and its application. The invention discloses a marker of schizophrenia and its application in preparing a kit for diagnosing schizophrenia, and also discloses a kit for detecting the marker. The schizophrenia markers disclosed in the present invention include Prevotella, Succinivibrio, Fusobacterium, Lactobacillus, and Megasphaera , Acidaminococcus, Citrobacter, Phascolarctobacterium, Coprococcus, Roseburia, Blautia 11 species At least 5 of the microorganisms. The marker provided by the invention can judge schizophrenia and normal people, the AUC is above 0.81, has good diagnostic efficiency, and can be used to prepare a kit for effectively diagnosing schizophrenia.

The invention provides application of Roseburia to treatment and prevention of obesity related disease. The invention provides the application of Roseburia to the treatment and prevention of obesity related diseases, and a composition for treatment and prevention of obesity related diseases, wherein the composition comprises drug, drink, food, or animal feed composition; besides, a method for reducing the weight and / or blood sugar is also provided.

The invention discloses a purpose of Moringaceae powder for regulating animal intestinal flora, and food and medicine containing Moringaceae powder. The Moringaceae powder can significantly increase the number of such probiotics in animal intestines as lactobacillus acetotoleran, butyrivibrio, Luosibairui Escherichia, Roseburia Stanton and Savage and the like and significantly regulate the animal intestinal flora, so as to achieve an effect for preventing and treating diabetes, hypertension and hyperlipidemia through the functions of the intestinal flora.

A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and may also be encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered, or a composition comprising modified L. reuteri bacteria having the ability to survive conditions in the duodenum or jejunum of the individual's small intestine. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Veillonella, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and Prevotella.

The invention discloses application of Fuzhuan tea in regulation of animal intestinal flora. The Fuzhuan tea can be used for obviously increasing the number of such probiotics in animal intestines as lactobacillus acetotoleran, butyrivibrio, Luosibairui Escherichia, Roseburia Stanton and Savage and the like and significantly regulating the animal intestinal flora, so as to achieve an effect of reducing blood fat through the functions of the intestinal flora.

The invention relates to the field of clinical microorganism detection, and provides a kit and a method for rapidly detecting and identifying mycobacteria in a clinical sample. The kit comprises two universal primers used for amplifying mycobacterium 16S rRNA variable region sequences, a specific primer used for shielding Rogowski bacterium 16S rRNA variable region, a specific primer used for shielding corynebacterium bacterium 16SrRNA variable region, a sequencing primer used for determining the sequence of a forward segment of amplified mycobacterium specific fragment, and avidin-labeled magnetic beads. A sequencing result is compared with a database to judge species. The kit can be used for detecting and identifying mycobacteria in clinical samples, and can be used for clinical diagnosis of suspected mycobacteria infection in various clinical samples. The kit not only wins precious rescue time for clinical diagnosis and treatment, but also has the advantages of being low in cost, convenient to operate and high in specificity.

A method for reducing the likelihood of developing depression in an individual involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of bacterial species able to make small chain fatty acids, and preferably butyrate, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. The individual's gut microbiome is modified to reduce the number of undesired bacteria and to increase the number of beneficial bacteria. Bacteria are preferably modified to remove one or more virulence facts or alternatively to produce increased amounts of SCFA's, such as butyrate. Beneficial bacteria may be encapsulated in a frangible enclosure to ensure they arrive in an individual's body while still viable, e.g. such as being first released in the lower gut rather than being exposed to the harsh conditions of an individual's stomach. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and L. casei to treat depression.

The present invention provides a method, wherein the method treats a subject having a dysbiosis, the method comprising: determining a first metabolic profile of the gut microbiome of a subject having a dysbiosis; changing the first metabolic profile of the gut microbiome of the subject to a second metabolic profile of the gut microbiome of the subject, by administering to the subject a composition comprising at least one bacterial species selected from the group consisting of: Acidaminococcus intestinalis, Bacteriodes ovatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia sp., Clostridium sp., Collinsella aerofaciens, Escherichia coli, Eubacterium desmolans, Eubacterium eligens, Eubacterium limosum, Faecallbacterum prausnitzii, Lachnospira pectinoshiza, Lactobacillus casei, Parabacteroides distasonis, Roseburia faecalis, Roseburia intestinalis, Ruminococcus sp., Ruminococcus species, and Ruminococcus torques, wherein the composition is administered at a therapeutically effective amount, sufficient to alter the first metabolic profile of the gut microbiome to the second metabolic profile of the gut microbiome.

The invention belongs to the technical field of medicines, and relates to application of intestinal Rosebariella in preparation of a tumor radiosensitizer. Research finds that the Roseburia intestinae can significantly improve the sensitivity of colorectal cancer to radiotherapy, which shows that after a colorectal cancer model mouse subjected to intragastric administration by the Roseburia intestinae is subjected to radiotherapy, the number of nodule is reduced, the size is reduced, the proliferation inhibition effect of colorectal cancer cells is improved, and the Roseburia intestinae can be used for preparing a colorectal cancer model mouse with the Roseburia intestinae. And the inflammation degree of the intestinal tract of the mouse subjected to local abdominal irradiation is reduced, so that the intestinal Rosiberia can be used as a tumor radiosensitizer, and the intestinal inflammation level is reduced.

A method for reducing the likelihood of developing depression in an individual involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of bacterial species able to make small chain fatty acids, and preferably butyrate, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. The individual's gut microbiome is modified to reduce the number of undesired bacteria and to increase the number of beneficial bacteria. Bacteria are preferably modified to remove one or more virulence facts or alternatively to produce increased amounts of SCFA's, such as butyrate. Beneficial bacteria may be encapsulated in a frangible enclosure to ensure they arrive in an individual's body while still viable, e.g. such as being first released in the lower gut rather than being exposed to the harsh conditions of an individual's stomach. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and L. casei to treat depression.

The invention belongs to the field of life science, particularly relates to a new application of Roseburia in preventing and treating anxiety disorder and depression, and provides an application of Roseburia in preparation of a drug for preventing and treating anxiety disorder and depression. The use amount of Roseburia viable bacteria is 1*10<4> to 1*10<20> CFU/mL every day.

The invention discloses a system for early prediction of postpartum subclinical ketosis of dairy cows based on intestinal microorganisms, the postpartum subclinical ketosis of dairy cows is predicted by using the abundance of intestinal prognostic marker microorganisms of dairy cows at the early perinatal stage, and the prognostic marker microorganisms comprise the genus level Parabacterides, Shigiella, Cellulosilylium, Roseburia, Sporobacter and Actinaerobacterium. Prognostic marker microorganisms of the six subclinical ketodiseases are screened, and a prognostic discrimination model is established based on discriminant analysis. The method has accurate and stable prediction capability on the postpartum subclinical ketosis of the dairy cows, can perform early warning screening on the perinatal dairy cows through a non-invasive rectum sampling method, and provides an effective means for preventing and treating the postpartum ketosis and the subclinical ketosis of the dairy cows as soon as possible in a dairy farm.

A method for increasing gastric tract acid (GTA) production in a mammalian subject. The method comprises administering a therapeutically-effective amount of a composition comprising at least one live or attenuated culture of a microbial species selected from the genus Blautia, species Faecalibacterium prausnitzii, genus Bacteroides, family Ruminococcaceae, family Lachnospiraceae, genus Coprococcus, genus Roseburia, genus Oscillospira, species Ruminococcus bromii, genus Ruminococcus, family Costridiaceae, species Dorea formicigenerans, species Bacteroides uniformis, genus Dorea, genus Streptococcus, order Clostridiales, genus Anaerostipes, genus Dialister, species Bifidobacterium adolescentis, family Coriobacteriaceae, genus Faecalibacterium, genus Sutterella, species Bacteroides ovatus, genus Parabacteroides, genus Ruminococcus, species Bacteroides faecis, species Eubacterium biforme, genus Phascolartobacterium, and family Enterobacteriaceae; or a prebiotic composition which increases growth and/or viability of said microbial species in the gut. Administering the composition increases the synthesis of at least one GTA dicarboxylic fatty acid metabolite in said subject. Also described are method for determining gastrointestinal inflammation status and kits for detecting and treating a gastric tract acid (GTA) insufficiency.

The invention discloses a method for early warning or noninvasive diagnosis of fatty liver cows by using fecal microorganisms at a genus level. The biomarker is characterized in that the biomarker is an anaerobic plush bacterium, a Roseburia bacterium and a Bifidobacterium bacterium at the genus level in the fecal microorganisms, and the biomarker is an anaerobic plush bacterium, a Roseburia bacterium and a Bifidobacterium bacterium at the genus level in the fecal microorganisms. Diagnostic ability verifies that the AUC value of the marker conforms to diagnostic significance, and the marker has higher clinical diagnosis application value; more importantly, the diagnosis capability of conjoint analysis of the three groups of microorganisms has better effects on moderate fatty liver and severe fatty liver. When the biomarker is used for diagnosing, identifying and monitoring the fatty liver dairy cow, the cost is low, the operation is simple, the biomarker is a non-invasive and non-invasive detection means, the concepts of animal welfare and healthy breeding are met, and the biomarker can be widely applied to large-scale breeding of dairy cows in the future to promote the development of the milk industry.